Correction: Targeting Brd4 for cancer therapy: inhibitors and degraders
Abstract
Correction for ‘Targeting Brd4 for cancer therapy: inhibitors and degraders’ by Yingchao Duan et al., Med. Chem. Commun., 2018, 9, 1779–1802.
Maintenance work is planned from 09:00 BST to 12:00 BST on Saturday 28th September 2024.
During this time the performance of our website may be affected - searches may run slowly, some pages may be temporarily unavailable, and you may be unable to access content. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a School of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China
b
Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China
E-mail:
zzuyubin@hotmail.com, liuhm@zzu.edu.cn
Correction for ‘Targeting Brd4 for cancer therapy: inhibitors and degraders’ by Yingchao Duan et al., Med. Chem. Commun., 2018, 9, 1779–1802.
Y. Duan, Y. Guan, W. Qin, X. Zhai, B. Yu and H. Liu, Med. Chem. Commun., 2019, 10, 181 DOI: 10.1039/C9MD90001B
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content